FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for FRUZAQLA, an oral targeted therapy for previously treated adults with metastatic colorectal cancer.
OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for OJJAARA, an oral treatment for adults with myelofibrosis and anemia.
Video Transcript: Risk-Based Care: Personalized care for better patient outcomes
This transcript explains how Biologics by McKesson’s Risk-Based Care program uses personalized nursing support to help patients stay on therapy and improve outcomes.
Video Transcript: Risk-Based Care: Personalized care for better outcomes | Dan & Porscha
This transcript highlights Biologics by McKesson’s Risk-Based Care program through Dan’s treatment journey and the personalized support provided by nurse Porscha Scales.
VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for VANFLYTA, approved for newly diagnosed FLT3-ITD positive acute myeloid leukemia in combination and maintenance settings.
Improving Oncology Patient Outcomes: The Future of Risk-Based Care
Research shows that Biologics by McKesson’s pioneering risk-based care program maximizes patients’ time on therapy, leading to better oncology patient outcomes.
Video Transcript: Patient Spotlight – Dan W. and Nurse Porscha Scales
Dan W. and nurse Porscha Scales discuss his leukemia diagnosis, treatment experience, and the ongoing support he received through Biologics by McKesson.
Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia
Biologics by McKesson became the sole specialty pharmacy provider for SKYCLARYS, the first approved treatment for Friedreich’s ataxia in adults and adolescents ages 16 and older.
JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for JAYPIRCA, approved for adults with relapsed or refractory mantle cell lymphoma after at least two prior therapies.
ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for ORSERDU, approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy.